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Abstract:  
Prescription central nervous system depressants, opioid pain relievers, and stimulants provide 
therapeutic value, but misuse for their recreational value is a growing problem in the United States. 
Because health insurance lowers the cost of purchasing prescription drugs, losing coverage may 
cause individuals to forgo treatment and decrease prescription drug consumption which could 
reduce health and increase the likelihood of overdose and death if individuals substitute to using 
illicit drugs. Using a regression discontinuity design, I estimate the effect of aging out of the federal 
dependent coverage mandate at age 26 on legal purchases of prescription central nervous system 
depressants, opioids, and stimulants. Individuals are 0.8-1 percentage points less likely to purchase 
a prescription central nervous system depressant and 1-2.6 percentage point less likely to purchase 
a prescription opioid after turning 26. These effects are strongest for women, while estimated 
effects for men are generally negative but imprecise.  
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1. Introduction 
The federal dependent coverage mandate (FDCM), part of the 2010 Patient Protection and 
Affordable Care Act (PPACA), aimed to increase insurance coverage and access to care among 
young adults by requiring family insurance plans to cover dependent children until their 26th 
birthday. This expansion of coverage led to increases in insurance coverage and utilization among 
young adults (Antwi, Moriya, and Simon, 2013; Barbaresco, Courtemanche, and Qi, 2015; 
Amuedo-Dorantes and Yaya, 2016). Individuals with health insurance are more likely to purchase 
prescription drugs because insurance decreases the cost of prescriptions and increases contact with 
healthcare providers.1 Partial or full reductions in insurance coverage after aging out of the 
dependent coverage mandate at 26, therefore, may cause young adults to forgo prescription 
medications which can have serious health consequences for individuals who rely on prescription 
medication to maintain or improve their health, while nonmedical users of prescription drugs may 
substitute to illicit drugs and riskier health behaviors. 
I focus on purchases of prescription central nervous system (CNS) depressants, opioids, 
and stimulants, medications that are generally used to treat anxiety, pain, and attention-deficit 
disorders, respectively. Forgoing medically necessary treatments likely decreases health, and for 
these drugs, abruptly decreasing consumption can cause individuals to experience serious medical 
issues, including seizures and death. Because CNS depressants, opioids, and stimulants have 
recreational value, they are the most commonly misused prescription medications. Nonmedical 
use of prescription medications is a growing problem in the United States. Nearly 17 million people 
age 12 or older in the United States reported misusing prescription drugs in 2017, and adults age 18 
to 25 have highest rates of prescription medication misuse (Substance Abuse and Mental Health 
Services Administration, 2019; Schulenberg et al, 2019). By drug class, 9.9 million people reported 
misuse of prescription opioids, 6.4 million reported misuse of prescription CNS depressants, and 
5.1 million reported misuse of prescription stimulants (Substance Abuse and Mental Health 
Services Administration, 2019). Misuse of prescription medications is associated with using illegal 
drugs (Compton and Volkow, 2006; Compton, Jones, and Baldwin 2016) and the recent opioid 
epidemic in the United States (Jones, Mack, and Paulozzi, 2013). Individuals who use these 
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 In the main sample used in this paper, a simple regression shows insurance coverage is associated with a 20 
percentage point increase in the likelihood of purchasing any prescription drug.  
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medications for the recreational high value may also substitute to black market drugs which can 
cause additional negative health effects.  
I examine the question of whether insurance coverage affects prescription drug purchases 
using the PPACA’s federal dependent coverage mandate which allows dependent children to be 
covered until the individual turns 26 years old. I find young adults are 2.8-4.4 percentage points 
less likely to have health insurance, 0.8-1 percentage points less likely to purchase a prescription 
CNS depressant, and 1.-2.6 percentage points less likely to purchase a prescription opioid after 
turning 26 years old. Estimated effects on prescription stimulant purchases are negative but 
statistically insignificant. The results for prescription purchases are stronger for women who are 
1.4-1.9 percentage points less likely to purchase a CNS depressant and 1.2-4.7 percentage points 
less likely to purchase an opioid. Given the potential negative health effects associated with 
decreased use of these prescription drugs, these results indicate important areas to target for 
policymakers and healthcare practitioners.  
2. Background 
2.1 Federal dependent coverage mandate 
President Obama signed the PPACA in March 2010 with the goal of expanding access to healthcare 
and reducing costs. One of the major components of the PPACA was the federal dependent 
coverage mandate that expanded insurance coverage to young adults. This policy went into effect 
in late September 2010 and requires insurers to cover family policyholder’s children until their 26th 
birthday. Before the policy change, family plans generally only covered children until age 18, and 
29 percent of young adults were uninsured, the highest rate of uninsurance among all age groups 
(Nicholsen et al, 2009).2  Prior work shows the FDCM increased insurance coverage (Antwi, 
Moriya, and Simon, 2013; Barbaresco, Courtemanche, and Qi, 2015; Amuedo-Dorantes and Yaya, 
2016),utilization (Barbaresco, Courtemanche, and Qi, 2015), and the likelihood of purchasing 
prescription medications for young adults under age 26 (Amuedo-Dorantes and Yaya, 2016; Pakyz, 
Wang, and Cunningham, 2017).3 Other work focuses on the effect of aging out of the FDCM at 26, 
                                                          
2
 Prior to the federal dependent coverage mandate, some states had dependent coverage mandates with different 
restrictions on eligibility that depended on age, school enrollment, and marital status.  
3
 Other ACA policies such as health insurance subsidies, Medicaid expansions, and the individual health insurance 
mandate also likely contributed to increasing insurance coverage among young adults either directly or indirectly 
through insurance gains for their parents. 
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finding increases in uninsurance (Dahlen, 2015; Lee, 2018; Yoruk, 2018) and reports of worse 
coverage for those who remain insured (Dahlen, 2015). Lee (2018) provides evidence that aging 
out of the FDCM does not affect the demand for preventative care or risky health behaviors for 
adults under 26. Pakyzx, Wang, and Cunningham (2017) find the FDCM is associated with an 
increase in prescription expenditures and a decrease in out-of-pocket expenditures, with the CNS 
depressants as one of the most common medications. Breslau et al (2017) do not find evidence the 
FDCM increased risky substance use for adults under 26. Wettstein (2019) finds a 1 percentage 
point increase in coverage due to the mandate reduced opioid mortality among young adults by 
about 2.5 per 100,000 population (20 percent).  
2.2 CNS depressants, opioids, stimulants and insurance coverage 
Figure 1 shows trends in prescription rates for CNS depressants, opioids, and stimulants for young 
adults age 18-25 years old and 26-30 years old during the sample period from 2011-2017. The share 
of 18-25 year-olds who purchased a prescription CNS depressant increased from about 2.5 percent 
to 3.5 percent, while the share declined slightly from 4 percent to 3.75 percent for 26-30 year-olds. 
The 26-30 year-old group was more likely to purchase opioids, but the downward trend is similar 
for both groups over this period, likely due to changes in prescribing practices, prescription drug 
monitoring programs, and the 2010 reformulation of OxyContin. Stimulant prescription rates were 
relatively flat for the 18-25 group (6-7 percent), while the share roughly doubled from 3 percent to 
just over 6 percent for the 26-30 group.  
Therapeutic uses for these drugs vary. CNS depressants are a class of drugs that include 
barbituates, benzodiazepines such as alprazolam (e.g. Xanax), and sleeping aids such as zolpidem 
(e.g. Ambien) and are commonly used to treat seizures, anxiety, and insomnia, respectively. 
Opioids (e.g. OxyContin) are used for pain relief, and stimulants such as methylphenidate (e.g. 
Ritalin) and dextroamphetamine/amphetamine (e.g Adderall) are used to treat attention-deficit 
disorders. These prescription medications also have the potential for misuse due to their 
recreational consumption value. Young adults cite various reasons for using prescription drugs 
(Rabiner et al., 2009; McCabe et al., 2007; Lord, Brevard, and Budman, 2011). For example, 
stimulants are often used to study and increase alertness (Rabiner et al., 2009), while opioids are 
often used to relieve pain and get “high” (McCabe et al., 2007; Lord, Brevard, and Budman, 2011). 
Misuse of prescription drugs is associated with addiction and illegal drug use. Nonmedical use of 
prescription pain relievers, for example, has been linked to later heroin use (Lankenau et al, 2012; 
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Jones, 2013; Muhuri, Gfroerer, and Davies, 2013). Polysubstance misuse is also an issue because 
combinations such as benzodiazepines and opioids have reinforcing effects (Jones, Mogali, and 
Comer, 2012).   
 Since insurance increases access to care and reduces the cost of prescription medications, 
losing insurance or having less full insurance (i.e. higher co-pays for prescription drugs) from 
aging out of the FDCM at 26, should reduce prescription purchases if demand is price elastic. 
Forward-looking individuals who expect to lose insurance coverage at 26 may attempt to smooth 
consumption through the insurance loss by reducing current consumption or, if possible, increasing 
current period prescription purchases to save for future consumption. The health effects from 
decreased use of these prescriptions will vary depending on the medication, past consumption, and 
reason for use. Long-term users of CNS depressants, opioids, and stimulants, whose use is for 
medical or nonmedical reasons, may become physiologically dependent on these drugs, and 
decreased consumption or withdrawal can negatively affect health. Withdrawal symptoms vary.4 
Tapering consumption of benzodiazepines for long-term users is recommended (Lader, Tylee, and 
Donoghue, 2009) because withdrawal can result in anxiety, seizures, and, in some cases, death. 
Opioid withdrawal symptoms such as anxiety, hot and cold flushes, muscle cramps, nausea, and 
vomiting may last for a few days or a few weeks. Stimulant withdrawal symptoms are less severe, 
and generally include depression, irritability, and muscle aches. Decreased consumption by 
individuals who use prescription drugs for therapeutic reasons will experience further reductions 
in health, although this could be lessened if relatively cheaper substitutable medications or 
treatments are available. An increase in the cost of legal prescriptions decreases the relative price 
of substitutes in the black market, and this may cause nonmedical users to substitute towards drugs 
like heroin in the case of nonmedical opioid users (Muhuri, Gfroerer, and Davies, 2013). Illicit drug 
quality is often unknown, and impurities are associated with an increased likelihood of overdose 
and death (Darke et al, 1999).  
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 A detailed discussion of withdrawal symptoms and treatments for substance abuse for many commonly abused 
drugs can be found in a guide for substance abuse counselors and clinicians, “TIP 45: Detoxification and Substance 
Abuse Treatment” produced by the U.S. Department of Health and Human Services, Substance Abuse and Mental 
Health Services Administration. Available at https://store.samhsa.gov/product/TIP-45-Detoxification-and-
Substance-Abuse-Treatment/SMA15-4131. Accessed October 9, 2019. 
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3. Data 
I use data from the 2010-2017 Medical Expenditure Panel Survey (MEPS), excluding data before 
October 2010 since the FDCM did not go into effect until September of that year. The MEPS 
interviews individuals five times over two years, and approximately 30,000 individuals are 
interviewed each year. It includes detailed information on health insurance coverage, utilization of 
healthcare services, the cost of these services, and how these services are paid for. More 
specifically, I use the MEPS full-year files that includes data on individual demographic and 
insurance information (insured during the survey round) and link this to the prescribed medicines 
files that contains information on prescription medications purchased in each survey round. The 
prescription data includes the drug name, national drug code, quantity, strength, form, days 
supplied, and amount paid. Using the detailed information on the prescription drugs purchased by 
individuals in the MEPS, I am able to narrowly focus on purchases of CNS depressants, opioids, 
and stimulants. Each individual in the MEPS may have up to five survey round observations, and 
while the MEPS is a short panel, I treat the data as pooled cross-sections. Table 1 shows the 
summary statistics for the main sample of individuals who are 36 months before or after their 26th 
birthday. A quarter of the sample is uninsured, and individuals who are at least 26 years old have 
higher rates of uninsurance (25 percent) relative to the younger group (24 percent). About 1.6 
percent of the older group purchased a prescription CNS depressant compared to 1.7 percent of the 
younger group. The shares purchasing a prescription opioid or stimulant are similar across both 
groups, 4.3 percent and 1.6 percent, respectively.  .  
4. Empirical strategy 
Consider a regression to estimate the effect of uninsurance (𝐷𝑖) on individual purchases of a 
prescription drug (𝑦𝑖), controlling for observable characteristics (𝑿𝒊): 
      𝑦𝑖 =  𝛽0 + 𝛽1𝐷𝑖 + 𝜸′𝑿𝒊 + 𝜖𝑖                                                      (1) 
The estimate of 𝛽1will be biased if unobservable individual characteristics such as risk preferences, 
discount factors, or underlying medical conditions are correlated with health insurance coverage 
and purchasing prescription drugs.  
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 To address the endogeneity of health insurance coverage, I use a regression discontinuity 
design (RDD) that exploits the FDCM rule that dependent children lose access to their family’s 
health insurance coverage at age 26. The RDD identification strategy relies on the assumption that 
individuals who are just below and just above an arbitrary cutoff, in this case being 26 years old, 
have similar observable and unobservable characteristics.5 The federal dependent mandate creates 
exogenous variation in health insurance coverage at the cutoff age of 26 since individuals cannot 
change their age.6 I calculate an individual’s age in months at the beginning of each survey round 
using the  birth month and  year of the respondent and survey round month and year.7  
 Figures 2 plots the share uninsured and the shares who purchased a prescription CNS 
depressant, opioid, or stimulant by age in months for individuals within a three-year window 
around age 26. Linear fits are on either side of the cutoff in each panel. There is a clear jump in 
uninsurance at age 26. Figure 2 shows decreases in the share purchasing prescription CNS 
depressants and opioids. These differences are most apparent for opioids, while the decrease in 
stimulants is less clear.  
 To formally estimate the effect of aging out of the federal dependent coverage mandate at 
age 26 on uninsurance and prescription drug purchases, I estimate the following equation: 𝑦𝑖 =  𝛽0 + 𝛽1𝐷𝑖 + 𝜆𝑎𝑔𝑒𝑖 + 𝛿(𝐷𝑖 × 𝑎𝑔𝑒𝑖) +  𝜸′𝑿𝒊 + 𝜖𝑖                          (2) 
Where 𝑦𝑖 is an outcome for individual 𝑖: an indicator for no health insurance coverage during the 
interview round and, separately, indicators for whether an individual purchased prescription CNS 
depressants, opioids, or stimulants during the survey round. 𝐷𝑖 is an indicator variable equal to one 
if the respondent is at least 26 years old in the first month of the survey round and 𝑎𝑔𝑒𝑖 is the 
running variable, age in months, centered on age 26 and zero months. 𝛽1 is the effect of turning 26 
on one of the previously described outcomes. 𝑿𝒊 is a vector of indicator variables that control for 
individual and survey characteristics including gender, marital status (married during survey 
round), race/ethnicity (black, Hispanic, Asian, and other race/ethnicity; white omitted), highest 
                                                          
5 While I cannot test the assumption that unobservable characteristics are similar around cutoff, I test for discontinuities 
of the control variables in vector 𝑿𝒊. These results, in Appendix Table A1, provide evidence that observable characteristics are similar around the cutoff.  
6
 Appendix Figure A1 shows there is no bunching of observations around the cutoff. 
7 I drop individuals who turn 26 in the month of the survey round because I do not accurately know their date of birth. 
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level of education (high school diploma, some college or associate’s degree, bachelor’s degree, 
and more than bachelor’s degree; less than a high school diploma omitted), region of the country 
(Midwest, South, and West; Northeast omitted), survey year, and first month of the survey round. 
I fit a linear function of age in months on either side of the cutoff because higher order polynomials 
reduce power with small sample sizes and the plots in Figures 2-4 suggest linearity in outcomes 
on either side of the cutoff.8 I estimate equation (1) using the main bandwidth of individuals who 
are 36 months before and after their 26th birthday as well as larger (48 months) and smaller (24 
months) bandwidths on either side of the cutoff. I also estimate the discontinuities at 26 using bias-
corrected, robust local linear estimators (Calonico, Cattaneo, and Titiunik, 2014). All specifications 
are estimated using survey weights and standard errors are clustered on age in months. 
 I also explore whether the effect of aging out of the FDCM on insurance coverage and 
prescription purchases varies by gender because of differences in healthcare utilization, 
prescription drug use, pharmacological response, and substance use disorders. Women are more 
likely to use prescription CNS depressants and opioids, while men are more likely to use 
prescription stimulants (Roe, McNamara, Motheral, 2002; Olfson, King, and Schoenbaum, 2015; 
Serdarevic, Striley, and Cottler, 2017; Hachtel and Armstrong, 2019). Men and women may also 
respond differently to drugs because of biological differences (Anderson, 2008; Pisanu et al, 2019). 
While men tend to have higher rates of substance use, the gender gap varies across drugs, and 
prescription drug misuse is similar between genders (McHugh et al, 2018). Figures 3 and 4 plot the 
outcomes for men and women, respectively. Women are less likely to be uninsured than men and 
are more likely to have purchased CNS depressants and opioids. Both figures show jumps in 
uninsurance at 26. For men, Figure 2 shows a decrease in the share purchasing an opioid, and 
Figure 3 shows a decrease in CNS depressants and opioids for women.  
                                                          
8
 The estimates from regressions that include a quadratic polynomial on either side of the cutoff provide similar 
results to the main estimates. Estimated effects on insurance are similar in sign, magnitude, and statistical 
significance, while effects on prescription purchases are similar in sign and magnitude but generally imprecise in 
these specifications. These results are in Appendix Table A2. 
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5. Results 
5.1 Main estimates 
I first concentrate on the effect of aging out of the FDCM at 26 on the likelihood of being 
uninsured. Table 2 shows these estimates across multiple specifications that vary the bandwidth 
around 26, inclusion of controls, and local polynomial estimators. I find that aging out of the 
federal dependent coverage mandate at 26 increases the probability of being uninsured by 2.8-4.1. 
These estimates are between 14-18 percent of the sample means and similar to previous estimates 
(Dahlen, 2015; Lee, 2018; Yoruk, 2018).  
 Next, I turn to the question of whether purchases of addictive prescription drugs change 
after age 26. Table 3 shows the reduced-form or intent-to-treat estimated effects of being at least 
26 years old on the likelihood of purchasing CNS depressants, opioids, or stimulants. Columns 1 
and 2 in Table 3 show the estimated effects on the likelihood of purchasing a prescription CNS 
depressant. The parametric estimates are all negative and the estimates using the 36 and 48-month 
bandwidth samples, which increase power, are statistically significant. Local linear regression 
estimates are similar, but slightly smaller in magnitude. These estimates suggest the likelihood of 
purchasing a CNS depressant decreases by 0.5-1 percentage points. The parametric estimates in 
columns 3 and 4 suggest the likelihood of purchasing an opioid at age 26 decreases by about 1 
percentage point. The local linear regressions, which place more weight on the area close to the 
cutoff, produce larger and statistically significant estimates, indicating the likelihood of purchasing 
an opioid decreases by 2.5-2.6 percentage points. These larger estimates are consistent with the 
drop in the share of individuals with a prescription opioid purchase near age 26 in Figure 2. The 
estimated effects on prescription stimulants are all negative, but imprecise. Given the standard 
errors, I am unable to detect effects smaller than a 0.8-1.4 percent point decrease in stimulant 
purchases. These results are consistent with the idea that losing health insurance coverage increases 
the cost of prescription drugs and reduces the likelihood of purchasing these prescription drugs.    
5.2 Effects by gender 
Table 4 shows the estimated change in the likelihood of being uninsured after 26 by gender. These 
estimates show men are 3.6-4.2 percentage points more likely to be uninsured after 26. For women, 
being at least 26 years old increases the likelihood of uninsurance by 2.3-4.0 percentage points.  
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Table 5 shows the reduced form effects of being at least 26 years old on the likelihood of 
purchasing prescription CNS depressants, opioids, or stimulants for men. Only two of the estimates 
are statistically significant. The estimates provide suggestive evidence of a decreased likelihood 
of purchasing opioids and stimulants, while the effects for CNS depressants are mixed. In 
percentage points, I am unable to detect effects smaller than about 0.8-1.1 for CNS depressants, 1.1-
1.7 for opioids, and 2.2-5 for stimulants.   
The estimates for women in Table 6 show statistically significant decreases in the 
likelihood of purchasing a CNS depressant and purchasing an opioid at age 26. In every 
specification, the estimated effects on CNS depressants are negative and statistically significant. 
These estimates range from a 1.4-1.9 percentage point decrease in the likelihood of purchasing a 
CNS depressant. The likelihood of purchasing an opioid decreases by 1.2-1.6 percentage points 
under the parametric specifications. These estimates are statistically significant using the 36-month 
and 48-month bandwidth samples, while the estimates using the 24-month bandwidth are slightly 
smaller and less precise. Similar to the main results, the local linear regression estimates for opioids 
are statistically significant but much larger for opioids, and this large drop around the cutoff is 
evident in the opioids panel in Figure 4. The estimated effects on stimulants are negative but 
imprecise.  
6. Discussion  
Estimating the effect of insurance coverage on health-related outcomes such as prescription 
drug purchases is difficult since those who have coverage may differ in unobservable ways from 
those who do not have coverage. The federal dependent coverage mandate, which requires insurers 
to cover dependent children until age 26, creates the potential for a plausibly exogenous change in 
insurance coverage at 26 as individuals age out of the mandate. I use this rule to examine its effects 
on the likelihood of uninsurance and purchasing prescription CNS depressants, opioids, and 
stimulants, drugs with high rates of misuse. Reductions in insurance coverage may cause 
individuals to decrease purchases of CNS depressants, opioids, and stimulants which can create 
significant negative health effects from withdrawal. Because adults 18-25 years old have the 
highest rates of misusing prescription drugs, nonmedical users of these prescription drugs may  
substitute to illicit drugs, increasing the likelihood of negative health effects from illicit drug use, 
including overdose and death.  
  
10 
 
After age 26, I find individuals are 2.8-4.1 percentage points less likely to be insured, 0.5-
1 percentage points less likely to purchase a prescription CNS depressant, and 1-2.6 percentage 
points less likely to purchase a prescription opioid. Point estimates suggest individuals that are at 
least 26 years old are less likely to purchase prescription stimulants, but these effects are 
imprecisely estimated. Inflating the effects on prescription purchases by the change in insurance 
coverage suggests that individuals who lose insurance coverage from aging out of the mandate are 
26 percentage points less likely to purchase a CNS depressant and 31 percentage points less likely 
to purchase a prescription opioid.9 Consistent with previous studies that find women have higher 
rates of prescription CNS depressant and opioid use (Roe, McNamara, and Motheral, 2002); 
Olfson, King, and Schoenbaum, 2015; Serdarevic, Striley, and Cottler, 2017), I find women have 
higher rates of prescriptions for CNS depressants and opioids, and the negative effects on the 
likelihood of purchasing of these drugs are stronger for women.  
A back of the envelope calculation shows that about 37,000 individuals may not purchase 
a prescription CNS depressant after turning 26 and 47,000 may not purchase a prescription opioid, 
increasing the likelihood of health issues associated with decreased consumption of these drugs.10 
These estimates may overlap due to polysubstance use of CNS depressants and opioids so the total 
number affected may be lower. Policies and interventions targeted at individuals nearing their 26 
birthday who may be at risk of losing insurance coverage, particularly women with prescriptions 
for CNS depressants and opioids, may be beneficial to address the potential negative health 
consequences of reductions in consumption of prescription drugs.   
This analysis has some limitations and directions for future work. The estimated effects 
only apply to individuals around the cutoff because of the empirical design, so it is not possible to 
extrapolate how changes in insurance coverage affects prescription purchases for a broader 
population. I am unable to estimate whether consumption of prescriptions change since the data is 
                                                          
9
 These estimates are calculated from the specifications that include controls and a linear function of age on either 
side of the cutoff with the 36-month bandwidth sample. I divide the effect on CNS depressants (-0.008) and opioids 
(-0.010), separately, bv the estimated effect on uninsurance (0.032).  
10
 I calculate the number of women who do not purchase a prescription CNS depressant and prescription opioid at age 
26 by multiplying the estimated effect on the likelihood of purchasing the prescription drug by the age 26 population. 
The population estimate, 4,669,782, comes from the 2017 American Community Survey. I use the estimates from the 
specifications that include controls and a linear function of age on either side of the cutoff with the 36-month 
bandwidth sample. For CNS depressants, the calculation is (0.008 x 4,669,782) = 37,358. For opioids the calculation 
is (0.010 x 4,669,782) = 46,697. 
  
11 
 
limited to information about purchases. This is problematic because some individuals may change 
consumption due to expectations about future insurance coverage. For example, individuals may 
reduce consumption of their medication to save for future consumption in anticipation of losing 
insurance. I am also unable to test whether individuals substitute to drugs sold on the black market, 
either illegal prescriptions or illicit drugs such as heroin or methamphetamine. Future work can 
explore the relationship between aging out of the federal dependent coverage mandate and illegal 
drug use (identifying possible substitution effects), treatment for substance abuse, emergency 
hospitalizations related to drug abuse, and drug-related mortality. 
  
  
12 
 
References 
Amuedo-Dorantes, C. and Yaya, M. E. 2016. The Impact of the ACA’S Extension of Coverage to 
Dependents on Young Adults’ Access to Care and Prescription Drugs. Southern Economic 
Journal, 83(1): 25-44. 
Anderson, G. D. 2008. Gender Differences in Pharmacological Response. International Review of 
Neurobiology, 83: 1-10. 
Antwi, Y. A., Moriya, A. S., and Simon, K. 2013. Effects of Federal Policy to Insure Young 
Adults: Evidence from the 2010 Affordable Care Act’s Dependent-Coverage Mandate. 
American Economic Journal: Economic Policy, 5(4): 1-28. 
Barbaresco, S., Courtemanche, C. J., and Qi, Y. 2015. Impacts of the Affordable Care Act 
Dependent Coverage Provision on Health-related Outcomes of Young Adults. Journal of 
Health Economics, 40: 54-68. 
Breslau, J., Yu, H., Han, B., Pacula, R. L., Burns, R. M., and Stein, B. D. 2017. Did the Dependent 
Coverage Expansion Increase Risky Substance Use Among Young Adults? Drug and 
Alcohol Dependence, 178(1): 556-561. 
Calonico, S., Cattaneo, M. D., and Titiunik, R. 2014. Robust Nonparametric Confidence Intervals 
for Regression-Discontinuity Designs. Econometrica, 82(6): 2295-2326. 
Compton, W. M., Jones, C. M., Baldwin, G. T. 2016. Relationship between Nonmedical 
Prescription-Opioid Use and Heroin Use. New England Journal of Medicine, 374: 154-
163. 
Compton, W. M.  and Volkow, N. D. 2006. Abuse of Prescription Drugs and the Risk of Addiction. 
Drug and Alcohol Dependence, 83(1): S4-S7. 
Dahlen, H. M. 2015. “Aging Out” of Dependent Coverage and the Effects on US Labor Market 
and Health Insurance Choices. American Journal of Public Health, 105(S5): S640-S650. 
Darke, S., Hall, W., Weatherbun, D., and Brownwyn, L. 1999. Fluctuations in Heroin Purity and 
the Incidence of Fatal Heroin Overdose. Drug and Alcohol Dependence, 54(2): 155-161.  
Hachtel, J. C. and Armstrong, K. J. 2019. Illicit Use of Prescription Stimulants: Gender Differences 
in Perceptions of Risk. Substance Use & Misuse, 54(10): 1654-1662. 
Jones, C. M., Mack, K. A., and Paulozzi, L. J. 2013. Pharmaceutical Overdose Deaths, United 
States, 2010. Journal of the American Medical Association, 309(7): 657-659.  
Jones, J. D., Mogali, S., and Comer, S. D. 2012. Polydrug Abuse: A Review of Opioid and 
Benzodiazepine Combination Use. Drug and Alcohol Dependence, 125(1-2): 8-18. 
Lader, M., Tylee, A., and Donoghue, J. 2009. Withdrawing Benzodiazepines in Primary Care. 
CNS Drugs, 23(1): 19-34. 
  
13 
 
Lankenau, S.E., Teti, M., Silva, K., Bloom, J., Harocopos, A., and Treese, M. 2012. Initiation into 
Prescription Opioid Misuse Amongst Young Injection Drug Users. International Journal 
of Drug Policy, 23(1): 37-44. 
Lee, J. 2018. Effects of Health Insurance Coverage on Risky Behaviors. Health Economics, 27(4): 
762-777. 
Lord, S., Brevard, J., and Budman, S. 2011. Connecting to Young Adults: An Online Social 
network Survey of Beliefs and Attitudes Associated with Prescription Opioid Misuse 
Among College Students. Substance Use & Misuse, 46(1): 66-76. 
McCabe, S. E., Cranford, J. A., Boyd, C. J., Teter, C. J. 2007. Motives, Diversion and Routes of 
Administration Associated with Nonmedical Use of Prescription Opioids. Addictive 
Behaviors, 32(3): 562-575. 
McHugh, R. K., Votaw, V. R., Sugarman, D. E., and Greenfield, S. F. 2018. Sex and Gender 
Differences in Substance Use Disorders. Clinical Psychology Review, 66: 12-23. 
Muhuri, P. K., Gfroerer, J. C., Davies, C. 2013. Associations of Nonmedical Pain Reliever Use 
and Initiation of Heroin Use in the United States. CBHSQ Data Review. Rockville, MD: 
Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Retrieved from: https://www.samhsa.gov/data/. Accessed 
October 9, 2019.  
Nicholson, J. L., Collinson, S. R., Mahato, B., Gould, E., Schoen, C., and Rustgi, S. D. 2009. Rite 
of Passage? Why Young Adults Become Uninsured and How New Policies Can Help, 2009 
Update. Issue Brief (Commonwealth Fund), 64: 1-22.Pakyz, A., Wang, H., and 
Cunningham, P. 2017. Impact of Health Reform on Young Adult Prescription Medication 
Utilization. American Journal of Managed Care, 23(11): 670-676. 
Pisanu, C., Franconi, F., Gessa, G. L., Mameli, S., Pisanu, G. M., Campesi, I., Leggio, L., and 
Agabio, R. 2019. Sex Differences in the Response to Opioids for Pain Relief: A systematic 
review and meta-analysis. Pharmacological Research, 148: 1-11. 
Olfson, M., King, M., and Schoenbaum, M. 2015. Benzodiazepene Use in the United States. 
Journal of the American Medical Association, Psychiatry, 72(2): 136-142. 
Rabiner, D. L., Anastopoulos, A. D., Costello, E. J., Hoyle, R. H., McCabe, S. E., Swartzwelder, 
H. S. 2009. Motives and Perceived Consequences of Nonmedical ADHD Medication Use 
by College Students: Are Students Treating Themselves for Attention Problems? Journal 
of Attention Disorders, 13(3): 259-270. 
Roe, C. M., McNamara, A. M., and Motheral, B. R. 2002. Gender- and Age-related Prescription 
Drug Use Patterns. Annals of Pharmacotherapy, 36(1): 30-39. 
Schulenberg, J., Johnston, L., O’Malley, P., Bachman, J., Meich, R., and Patrick, M. 2019. 
Monitoring the Future National Survey Results on Drug Use 1975-2018: Volume 2, 
  
14 
 
College Students & Adults Ages 19-60. Ann Arbor: Institute for Social Research, The 
University of Michigan.  
Serdarevic, M., Striley, C. W., and Cottler, L. B. 2017. Sex Differences in Prescription Opioid 
Use. Current Opinion in Psychiatry, 30(4): 238-246. 
Substance Abuse and Mental Health Services Administration. 2019. Key Substance Use and 
Mental Health Indicators in the United States: Results from the 2018 National Survey on 
Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). 
Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and 
Mental Health Services Administration. Retrieved from: https://www.samhsa.gov/data/.  
Wettstein, G. 2019. Health Insurance and Opioid Deaths: Evidence from the Affordable Care Act 
Young Adult Provision. Health Economics, 28(5): 666-677. 
Yoruk, B. 2019. Health Insurance Coverage and Health Care Utilization: Evidence from the 
Affordable Care Act’s Dependent Coverage Mandate. Forum for Health Economics & 
Policy, 21(2): 1-24. 
 
 
   
 
  
  
15 
 
Figures 
Figure 1: Prescription purchases of CNS depressants, opioids, or stimulants by young adults, 
2011-2017 
 Note: Fraction of individuals, age 18-25 and 26-30 that purchased a prescription CNS depressant, opioid, or stimulant 
each year. Data from the 2011-2017 Medical Expenditure Panel Surveys. 
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Figure 2: Changes in insurance coverage and prescription purchases around 26 years old 
 Notes: Mean of outcomes in 1-month intervals for individuals who are between 36 months before and 36 months after 
their 26th birthday. Lines of best fit with confidence intervals are also shown on either side of age 26. Dashed red line 
at zero represents cutoff point, age 26 and zero months. Data from the 2010-2017 Medical Expenditure Panel Surveys. 
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Figure 3: Changes in insurance coverage and prescription purchases around 26 years old, men 
 Notes: Mean of outcomes in 1-month intervals for men who are between 36 months before and 36 months after their 
26th birthday. Lines of best fit with confidence intervals are also shown on either side of age 26. Dashed red line at 
zero represents cutoff point, age 26 and zero months. Data from the 2010-2017 Medical Expenditure Panel Surveys. 
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Figure 4: Changes in insurance coverage and prescription purchases around 26 years old, women 
 Notes: Mean of outcomes in 1-month intervals for women who are between 36 months before and 36 months after 
their 26th birthday. Lines of best fit with confidence intervals are also shown on either side of age 26. Dashed red line 
at zero represents cutoff point, age 26 and zero months. Data from the 2010-2017 Medical Expenditure Panel Surveys. 
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Tables 
Table 1: Summary statistics for 23-29 year olds 
 All 23-25 26-29 
Outcomes    
Uninsured 0.240 0.236 0.245 
    
Purchased CNS depressant 0.017 0.017 0.016 
    
Purchased opioid 0.043 0.043 0.043 
    
Purchased stimulant 0.016 0.016 0.016 
    
Controls    
Female 0.506 0.503 0.508 
    
Black 0.131 0.134 0.128 
    
Hispanic 0.207 0.210 0.203 
    
Asian 0.067 0.061 0.073 
    
Other race/ethnicity 0.030 0.032 0.029 
    
High school degree 0.271 0.286 0.256 
    
Some college 0.334 0.376 0.291 
    
Bachelor’s degree 0.261 0.238 0.285 
    
Post bachelor’s degree 0.059 0.029 0.089 
    
Married 0.284 0.203 0.368 
    
Northeast 0.171 0.168 0.173 
    
Midwest 0.218 0.217 0.219 
    
South 0.366 0.379 0.352 
    
West 0.245 0.236 0.255 
    
N 47,353 23,657 23,689 
Notes: Weighted sample means. Data from the 2010-2017 Medical Expenditure Panel Surveys. 
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Table 2: Change in likelihood of uninsurance at age 26 
 (1) (2) 
Panel A: 24-month bandwidth   
At least 26 years old  0.041*** 0.036*** 
 (0.011) (0.009) 
   
N: 31,705   
Panel B: 36-month bandwidth   
At least 26 years old  0.039*** 0.032*** 
 (0.009) (0.007) 
   
N: 47,353   
Panel C: 48-month bandwidth   
At least 26 years old  0.034*** 0.030*** 
 (0.008) (0.006) 
   
N: 63,000   
Panel D: local linear regression   
At least 26 years old 0.038 0.028** 
 (0.055) (0.011) 
   
   
Controls No Yes 
Notes: Standard errors clustered on age in months. Column (1) does not include individual or survey controls. 
Column (2) includes individual and survey controls. Individual and survey controls include age in months, sex, 
marital status (married during survey round), race/ethnicity (black, Hispanic, Asian, and other race/ethnicity; white 
omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than a 
bachelor’s degree; less than high school diploma omitted), region of the country (Midwest, south, and west; 
northeast omitted), survey year, and first month of the survey round. Parametric regressions include a linear fit of 
age in months on each side of the cutoff. Local linear regression estimated using triangular kernel. All regressions 
are estimated using survey weights. Data from the 2010-2017 Medical Expenditure Panel Surveys. * p < 0.10, ** p < 
0.05, *** p < 0.01 
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Table 3: Change in likelihood of purchasing of prescription CNS depressants, opioids, and stimulants at age 26 
  CNS depressants  Opioids  Stimulants 
  (1) (2)  (3) (4)  (5) (6) 
Panel A: 24-month bandwidth          
At least 26 years old   -0.006 -0.006  -0.010* -0.010*  -0.003 -0.003 
  (0.004) (0.004)  (0.005) (0.006)  (0.005) (0.005) 
          
N: 31,705          
Panel B: 36-month bandwidth          
At least 26 years old   -0.008** -0.008**  -0.010** -0.010**  -0.004 -0.004 
  (0.003) (0.003)  (0.005) (0.005)  (0.004) (0.004) 
          
N: 47,353          
Panel C: 48-month bandwidth          
At least 26 years old   -0.010*** -0.010***  -0.011*** -0.011**  -0.003 -0.003 
  (0.003) (0.003)  (0.004) (0.004)  (0.003) (0.003) 
          
N: 63,000          
Panel D: local linear regression          
At least 26 years old   -0.005 -0.007**  -0.025*** -0.026***  -0.007 -0.009 
  (0.004) (0.003)  (0.004) (0.003)  (0.009) (0.007) 
          
Controls  No Yes  No Yes  No Yes 
Notes: Standard errors clustered on age in months. Columns (1), (3), and (5) do not include individual and survey controls. Columns (2), (4), and (6) include individual 
and survey controls. Individual and survey characteristics include age in months, sex, marital status (married during survey round), race/ethnicity (black, Hispanic, 
Asian, and other race/ethnicity; white omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than a bachelor’s degree; 
less than high school diploma omitted), region of the country (Midwest, south, and west; northeast omitted), survey year, and first month of the survey round. 
Parametric regressions include a linear fit of age in months on each side of the cutoff. Local linear regression estimated using triangular kernel. All regressions are 
estimated using survey weights.  Data from the 2010-2017 Medical Expenditure Panel Surveys. * p < 0.10, ** p < 0.05, *** p < 0.01 
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Table 4: Change in likelihood of uninsurance at age 26, by gender 
  Men  Women 
  (1) (2)  (3) (4) 
Panel A: 24-month bandwidth       
At least 26 years old   0.042** 0.041***  0.040*** 0.032** 
  (0.017) (0.015)  (0.014) (0.013) 
       
N:   15,081  16,624 
Panel B: 36-month bandwidth       
At least 26 years old   0.039*** 0.039***  0.036*** 0.025** 
  (0.013) (0.012)  (0.012) (0.011) 
       
N  22,371  24,982 
Panel C: 48-month bandwidth       
At least 26 years old   0.036*** 0.037***  0.031*** 0.023** 
  (0.011) (0.010)  (0.010) (0.009) 
       
N:   29,860  33,140 
Panel D: local linear regression       
At least 26 years old  0.036 0.037*  0.039 0.024* 
  (0.067) (0.019)  (0.055) (0.013) 
       
       
Controls  No Yes  No Yes 
Notes: Standard errors clustered on age in months. Columns (1) and (3) do not include individual or survey controls. 
Columns (2) and (4) include individual and survey controls. Individual and survey controls include age in months, 
sex, marital status (married during survey round), race/ethnicity (black, Hispanic, Asian, and other race/ethnicity; 
white omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than 
a bachelor’s degree; less than high school diploma omitted), region of the country (Midwest, south, and west; 
northeast omitted), survey year, and first month of the survey round. Parametric regressions include a linear fit of 
age in months on each side of the cutoff. Local linear regression estimated using triangular kernel. All regressions 
are estimated using survey weights. Data from the 2010-2017 Medical Expenditure Panel Surveys. * p < 0.10, ** p < 
0.05, *** p < 0.01 
 
 
  
23 
 
Table 5: Change in likelihood of purchasing of prescription CNS depressants, opioids, and stimulants at age 26, men 
  CNS depressants  Opioids  Stimulants 
  (1) (2)  (3) (4)  (5) (6) 
Panel A: 24-month bandwidth          
At least 26 years old   0.006 0.006*  -0.009 -0.009  -0.005 -0.006 
  (0.004) (0.004)  (0.006) (0.006)  (0.008) (0.008) 
          
N: 15,081          
Panel B: 36-month bandwidth          
At least 26 years old   0.002 0.003  -0.006 -0.006  -0.007 -0.007 
  (0.003) (0.003)  (0.005) (0.005)  (0.006) (0.006) 
          
N: 22,371          
Panel C: 48-month bandwidth          
At least 26 years old   -0.005 -0.005  -0.007 -0.007  -0.002 -0.002 
  (0.003) (0.003)  (0.004) (0.004)  (0.005) (0.005) 
          
N: 29,860          
Panel D: local linear regression          
At least 26 years old   -0.000 -0.000  -0.007* -0.003  -0.017 -0.018 
  (0.004) (0.004)  (0.004) (0.005)  (0.018) (0.015) 
          
Controls  No Yes  No Yes  No Yes 
Notes: Standard errors clustered on age in months. Columns (1), (3), and (5) do not include individual and survey controls. Columns (2), (4), and (6) include individual 
and survey controls. Individual and survey characteristics include age in months, sex, marital status (married during survey round), race/ethnicity (black, Hispanic, 
Asian, and other race/ethnicity; white omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than a bachelor’s degree; 
less than high school diploma omitted), region of the country (Midwest, south, and west; northeast omitted), survey year, and first month of the survey round. 
Parametric regressions include a linear fit of age in months on each side of the cutoff. Local linear regression estimated using triangular kernel. All regressions are 
estimated using survey weights.  Data from the 2010-2017 Medical Expenditure Panel Surveys. * p < 0.10, ** p < 0.05, *** p < 0.01 
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Table 6: Change in likelihood of purchasing of prescription CNS depressants, opioids, and stimulants at age 26, women 
  CNS depressants  Opioids  Stimulants 
  (1) (2)  (3) (4)  (5) (6) 
Panel A: 24-month bandwidth          
At least 26 years old   -0.018*** -0.018***  -0.012 -0.012  -0.001 -0.010 
  (0.006) (0.006)  (0.010) (0.010)  (0.005) (0.005) 
          
N: 16,624          
Panel B: 36-month bandwidth          
At least 26 years old   -0.019*** -0.019***  -0.015* -0.015*  -0.001 -0.001 
  (0.005) (0.005)  (0.008) (0.008)  (0.005) (0.005) 
          
N: 24,982          
Panel C: 48-month bandwidth          
At least 26 years old   -0.016*** -0.016***  -0.015** -0.016**  -0.004 -0.004 
  (0.004) (0.004)  (0.007) (0.007)  (0.004) (0.004) 
          
N: 33,140          
Panel D: local linear regression          
At least 26 years old   -0.014** -0.017***  -0.044*** -0.047***  -0.002 -0.002 
  (0.007) (0.005)  (0.012) (0.010)  (0.008) (0.005) 
          
Controls  No Yes  No Yes  No Yes 
Notes: Standard errors clustered on age in months. Columns (1), (3), and (5) do not include individual and survey controls. Columns (2), (4), and (6) include individual 
and survey controls. Individual and survey characteristics include age in months, sex, marital status (married during survey round), race/ethnicity (black, Hispanic, 
Asian, and other race/ethnicity; white omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than a bachelor’s degree; 
less than high school diploma omitted), region of the country (Midwest, south, and west; northeast omitted), survey year, and first month of the survey round.  
Parametric regressions include a linear fit of age in months on each side of the cutoff. Local linear regression estimated using triangular kernel. All regressions are 
estimated using survey weights. Data from the 2010-2017 Medical Expenditure Panel Surveys. * p < 0.10, ** p < 0.05, *** p < 0.01 
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Appendix 
 
Figure A1: Frequency of observations by age in months 
 
Note: Frequency of observations in each month, 36 months before and after 26. Red line marks the cutoff point for 
the discontinuity at age 26 and zero months. Data from the 2010-2017 Medical Expenditure Panel Surveys. 
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Appendix Table A1: Test for changes in individual characteristics at age 26 
 (1) 
Female -0.007 
 (0.013) 
White -0.013 
 (0.012) 
Black 0.011* 
 (0.006) 
Hispanic -0.006 
 (0.008) 
Asian 0.005 
 (0.005) 
Other race/ethnicity 0.003 
 (0.003) 
Married -0.000 
 (0.011) 
Less than high school degree 0.010 
 (0.009) 
High school degree -0.002 
 (0.008) 
Some college 0.010 
 (0.010) 
Bachelor’s degree -0.019 
 (0.012) 
Post-bachelor’s degree -0.000 
 (0.005) 
Northeast  0.008 
 (0.009) 
Midwest  -0.011 
 (0.009) 
South  -0.001 
 (0.011) 
West  0.004 
 (0.010) 
  
N 47,353 
Notes: Standard errors clustered on age in months. All regressions include a linear fit of age in months on each 
side of the cutoff and are estimated using survey weights. Data from the 2010-2017 Medical Expenditure Panel 
Surveys. * p < 0.10, ** p < 0.05, *** p < 0.01 
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Appendix Table A2: Change in likelihood of uninsurance and prescription purchases at age 26, quadratic polynomial and 36-month 
bandwidth 
  Full sample  Men  Women 
  (1) (2)  (3) (4)  (5) (6) 
Panel A: uninsurance          
At least 26 years old   0.037*** 0.038***  0.033 0.039**  0.041** 0.038** 
  (0.013) (0.010)  (0.021) (0.019)  (0.017) (0.015) 
          
Panel B: purchased a CNS 
depressant 
         
At least 26 years old   -0.003 -0.003  0.008 0.008  -0.015** -0.015** 
  (0.004) (0.004)  (0.003) (0.005)  (0.006) (0.006) 
          
Panel C: purchased an opioid          
At least 26 years old   -0.009* -0.009  -0.010 -0.011  -0.009 -0.009 
  (0.006) (0.006)  (0.007) (0.007)  (0.011) (0.010) 
          
Panel D: purchased a stimulant          
At least 26 years old   -0.007 -0.007  -0.009 -0.010  -0.005 -0.005 
  (0.006) (0.006)  (0.010) (0.010)  (0.006) (0.006) 
          
Controls  No Yes  No Yes  No Yes 
N  47,353 47,353  22,371 22,371  24,982 24,982 
Notes: Standard errors clustered on age in months. Columns (1), (3), and (5) do not include individual and survey controls. Columns (2), (4), and (6) include individual 
and survey controls. Individual and survey characteristics include age in months, sex, marital status (married during survey round), race/ethnicity (black, Hispanic, 
Asian, and other race/ethnicity; white omitted), highest level of education (high school diploma, some college, bachelor’s degree, and higher than a bachelor’s degree; 
less than high school diploma omitted), region of the country (Midwest, south, and west; northeast omitted), survey year, and first month of the survey round.  All 
regressions include a second-degree polynomial of age in months on both sides of the cutoff and are estimated using survey weights. Data from the 2010-2017 Medical 
Expenditure Panel Surveys. * p < 0.10, ** p < 0.05, *** p < 0.01 
 
